Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Qiagen ( (QGEN) ) has shared an announcement.
Qiagen N.V. announced a significant update regarding its voting rights, as reported by the Netherlands Authority for the Financial Markets (AFM). The notification disclosed that BlackRock, Inc. holds a substantial indirect capital interest and voting rights in Qiagen, with a total holding of 10.02% capital interest and 11.17% voting rights. This development indicates BlackRock’s considerable influence and potential impact on Qiagen’s governance and strategic decisions, reflecting the importance of institutional investors in shaping the company’s future direction.
The most recent analyst rating on (QGEN) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products that enable the isolation, purification, and analysis of DNA, RNA, and proteins, serving a global market with a strong emphasis on innovation and quality.
Average Trading Volume: 1,420,411
Technical Sentiment Signal: Buy
Current Market Cap: $9.72B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.